Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents.
Tolksdorf C, Seidel A, Baume C, Moritz E, Saljé K, Lehmann K, Becker K, Garscha U, Thiele T, Schwedhelm E, von Lucadou M, Tzvetkov MV, Engeli S, Jedlitschky G, Rauch BH. Tolksdorf C, et al. Among authors: engeli s. Platelets. 2024 Dec;35(1):2413713. doi: 10.1080/09537104.2024.2413713. Epub 2024 Oct 30. Platelets. 2024. PMID: 39475058 Free article.
Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans.
Blöcher JA, Meyer-Tönnies MJ, Morof F, Rönnpagel V, Bethmann J, Vollmer M, Engeli S, Tzvetkov MV. Blöcher JA, et al. Among authors: engeli s. Clin Pharmacol Ther. 2025 Jan;117(1):250-260. doi: 10.1002/cpt.3454. Epub 2024 Nov 3. Clin Pharmacol Ther. 2025. PMID: 39488825 Free PMC article.
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Lüdde T, Roden M, Schattenberg JM, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators. Roeb E, et al. Z Gastroenterol. 2024 Jul;62(7):1077-1087. doi: 10.1055/a-2309-6052. Epub 2024 Jul 8. Z Gastroenterol. 2024. PMID: 38976985 German. No abstract available.
Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial.
Richter A, Truthmann J, Hummers E, Pereira JFM, Gágyor I, Schuster F, Witte A, Böhm S, Greser A, Kamin P, Stracke S, Dörr M, Bülow R, Engeli S, Chenot JF, Ittermann T. Richter A, et al. Among authors: engeli s. Trials. 2024 Apr 3;25(1):229. doi: 10.1186/s13063-024-08066-0. Trials. 2024. PMID: 38570873 Free PMC article. Clinical Trial.
Prescriptions for Potentially Inappropriate Medication (PIM).
Wohlgemuth A, Michalowsky B, Hoffmann W, Platen M, Engeli S, Wucherer D, Ittermann T. Wohlgemuth A, et al. Among authors: engeli s. Dtsch Arztebl Int. 2024 Jan 12;121(1):25-26. doi: 10.3238/arztebl.m2023.0181. Dtsch Arztebl Int. 2024. PMID: 38386944 Free PMC article. No abstract available.
Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design.
Truthmann J, Freyer Martins Pereira J, Richter A, Schuster F, Witte A, Böhm S, Greser A, Kamin P, Stracke S, Dörr M, Bülow R, Engeli S, Gágyor I, Hummers E, Chenot JF. Truthmann J, et al. Among authors: engeli s. Trials. 2023 Oct 5;24(1):643. doi: 10.1186/s13063-023-07666-6. Trials. 2023. PMID: 37798801 Free PMC article.
172 results